BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15976065)

  • 1. Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder: results after six successive instillations of 40 mg BCG.
    Mugiya S; Ozono S; Nagata M; Takayama T; Ito T; Maruyama S; Hadano S; Nagae H
    Jpn J Clin Oncol; 2005 Jul; 35(7):395-9. PubMed ID: 15976065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG].
    Mugiya S; Nagata M; Takayama T; Ozono S; Ito T; Maruyama S; Hadano S; Nagae H
    Hinyokika Kiyo; 2004 Jul; 50(7):469-73. PubMed ID: 15334890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
    Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
    Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
    Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
    Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
    Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.
    Losa A; Hurle R; Lembo A
    J Urol; 2000 Jan; 163(1):68-71; discussion 71-2. PubMed ID: 10604316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term results and complications of intravesical instillation of bacillus Calmette-Guerin for prophylaxis of bladder cancer recurrence].
    Irie A; Lee KE; Kadowaki K; Sawamura M
    Hinyokika Kiyo; 1994 Oct; 40(10):873-7. PubMed ID: 7992700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder.
    Koga H; Kuroda M; Kudo S; Yamaguchi A; Usami M; Suzuki T; Naito S
    Int J Urol; 2005 Feb; 12(2):145-51. PubMed ID: 15733108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder].
    Uekado Y; Kohjimoto Y; Iba A; Kikkawa K; Shintani Y; Shinka T
    Hinyokika Kiyo; 2006 Jun; 52(6):439-44. PubMed ID: 16848357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.
    Takenaka A; Yamada Y; Miyake H; Hara I; Fujisawa M
    Int J Urol; 2008 Apr; 15(4):309-13. PubMed ID: 18380817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.
    Mack D; Höltl W; Bassi P; Brausi M; Ferrari P; de Balincourt C; Sylvester R;
    J Urol; 2001 Feb; 165(2):401-3. PubMed ID: 11176382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?].
    Yamada Y; Hara I; Kumano M; Furukawa J; Yamanaka K; Kamidono S
    Hinyokika Kiyo; 2005 Aug; 51(8):539-43. PubMed ID: 16164270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 2-week maintenance regimen of intravesical instillation of bacillus Calmette-Guerin is safe, adherent and effective in patients with non-muscle-invasive bladder cancer: a prospective, multicenter phase II clinical trial.
    Kanagawa Urological Research Group (KURG)
    Jpn J Clin Oncol; 2012 Sep; 42(9):813-9. PubMed ID: 22761255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP; Greenberg RE; Steinberg GD
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intravesical bacillus Calmette-Guerin instillation therapy of recurrent superficial bladder carcinomas resistant to intravesical anti-cancer chemotherapy].
    Takeuchi S; Kihara K; Higashi Y; Fukui I; Oshima H
    Hinyokika Kiyo; 1989 Apr; 35(4):577-81. PubMed ID: 2735262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.